UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

The Lancet (British edition), 2017-02, Vol.389 (10071), p.815-822

2017

Volltextzugriff (PDF)

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

The New England journal of medicine, 2011-12, Vol.365 (26), p.2484-2496

2011

Volltextzugriff (PDF)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

BMC medical research methodology, 2013-12, Vol.13 (1), p.152-152, Article 152

2013

Volltextzugriff (PDF)

A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome

Trials, 2020-04, Vol.21 (1), p.315-315, Article 315

2020

Volltextzugriff (PDF)

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

The Lancet (British edition), 2011-12, Vol.378 (9809), p.2104-2111

2011

Volltextzugriff (PDF)

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data

The Lancet (British edition), 2020-10, Vol.396 (10260), p.1422-1431

2020

Volltextzugriff (PDF)

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

Statistics in medicine, 2011-08, Vol.30 (19), p.2409-2421

2011

Volltextzugriff (PDF)

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

The Lancet (British edition), 2010-10, Vol.376 (9747), p.1155-1163

2010

Volltextzugriff (PDF)

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

The lancet oncology, 2016-02, Vol.17 (2), p.243-256

2016

Volltextzugriff (PDF)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

European urology, 2019-07, Vol.76 (1), p.115-124

2019

Volltextzugriff (PDF)

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data

Statistics in medicine, 2015-09, Vol.34 (21), p.2881-2898

2015

Volltextzugriff (PDF)

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1066-1074

2016

Volltextzugriff (PDF)

Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics

BMC medical research methodology, 2024-06, Vol.24 (1), p.124-12, Article 124

2024

Volltextzugriff (PDF)

Correction: Multi‑arm multi‑stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics

BMC medical research methodology, 2024-07, Vol.24 (1), p.143-2, Article 143

2024

Volltextzugriff (PDF)

A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials

PLoS medicine, 2021-05, Vol.18 (5), p.e1003629-e1003629

2021

Volltextzugriff (PDF)

The effectiveness of interventions to disseminate the results of non-commercial randomised clinical trials to healthcare professionals: a systematic review

Implementation science : IS, 2024-02, Vol.19 (1), p.8-8, Article 8

2024

Volltextzugriff (PDF)

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial

JAMA oncology, 2021-04, Vol.7 (4), p.555

2021

Volltextzugriff (PDF)

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects

Statistics in medicine, 2002-08, Vol.21 (15), p.2175-2197

2002

Volltextzugriff (PDF)

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study

PLoS medicine, 2020-01, Vol.17 (1), p.e1003019-e1003019

2020

Volltextzugriff (PDF)

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

European journal of cancer (1990), 2017-10, Vol.84, p.88-101

2017

Volltextzugriff (PDF)

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

BMC medical research methodology, 2016-02, Vol.16 (16), p.16-16, Article 16

2016

Volltextzugriff (PDF)

The role of placebo control in clinical trials for neurodegenerative diseases

Nature medicine, 2023-11, Vol.29 (11), p.2682-2683

2023

Volltextzugriff (PDF)

1 – 25 von 301

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(288)
Mit Volltextzugriff
(278)

Publikationsform

Sprache

Englisch
(300)

Erscheinungsjahr

n.n

Thema

Science & Technology
(216)
Life Sciences & Biomedicine
(202)
Humans
(182)
Clinical Trials
(88)
Male
(84)
Oncology
(71)
Female
(61)
Middle Aged
(60)
Aged
(53)
Medical Research
(53)
Treatment Outcome
(53)
General & Internal Medicine
(48)
Randomized Controlled Trials As Topic
(48)
Medicine, General & Internal
(46)
Survival Analysis
(46)
Prostate Cancer
(45)
Medicine, Research & Experimental
(44)
Research & Experimental Medicine
(44)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(38)
Biological And Medical Sciences
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(38)
The Lancet
(31)
Trials
(20)
Current Controlled Trials In Cardiovascular Medicine
(18)
Statistics In Medicine
(18)
The Lancet Oncology
(17)
Lancet
(14)
Clinical Trials
(13)
Lancet Oncology/lancet. Oncology
(10)
European Urology
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics

Correction: Multi‑arm multi‑stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics

A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials

The effectiveness of interventions to disseminate the results of non-commercial randomised clinical trials to healthcare professionals: a systematic review

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

The role of placebo control in clinical trials for neurodegenerative diseases

Suchergebnisse filtern